Title: Observation of curative effect of drospirenone ethinylestradiol combined with levonorgestrel intrauterine releasing system in treatment of adenomyosis and detection of related hormone level
Abstract: Objective To explore the clinical efficacy of drospirenone ethinylestradiol combined with levonorgestrel intrauterine releasing system(LNG-IUS) in the treatment of adenomyosis, and the related hormone level was detected. Methods Patients(150 cases) with adenomyosis for the treatment in Junxian People's Hospital from June 2009 to June 2013 were randomly divided into treatment(75 cases) and control(75 cases) groups. The patients in the control group were placed LNG-IUS by specialized medical personnel in 3 d of menstrual period. The patients in the treatment group were po administered with Drospirenone Ethinylestradiol Tablets on the basis of the control group when LNG-IUS was placed, 1 tablet/d. Each cycle was 21 d, and patients took one cycle then stopped, without treatment for 7 d. The patients in two groups were treated for three cycles. Dysmenorrhea, menstrual volume, uterus volume, and bleeding time of vaginal intravenous drip in two groups were compared. And the levels of progesterone(PRL), estradiol(E2), follicle-stimulating hormone(FSH), and luteinizing hormone(LH) were determined in two groups before and after the treatment. Results After treatment, the score of dysmenorrheal and menstrual volume were significantly improved, and the differences was statically significant in the same group before and after treatment(P 0.05). Dysmenorrhea and PBAC scores in the treatment group were significantly lower than those in the control group followed up for 1 and 3 months, with significant difference between the two groups(P 0.05). After treatment, the uterine volumes in two groups were significantly decreased, and the difference was statically significant in the same group before and after treatment(P 0.05). The uterine volume in treatment group was significantly less than that in control group followed up for 1, 3, and 6 months, with significant difference between the two groups(P 0.05). After treatment, bleeding time of vaginal intravenous drip in treatment group was lower than that in control group(P 0.05). After treatment, E2 in treatment group was significantly higher, while the levels of FSH and LH were significantly reduced, and the difference was statistically significant before and after treatment. After treatment, these indicators in treatment group were statistically significant compared with the control group(P 0.05). Conclusion Drospirenone ethinylestradiol combined with LNG-IUS has a good clinical efficacy in the treatment of adenomyosis, can significantly improve the dysmenorrhea, and reduce menstrual volume and bleeding time of vaginal intravenous drip, which is worthy of clinical application.
Publication Year: 2014
Publication Date: 2014-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot